Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, we aim to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. We are applying a 360-degree approach to small molecule drug design to build a pipeline based on the promise of this rapidly emerging biopharmaceutical field.
Company Details
- Founded
- -
- Address
- 430 E 29th St, New York,10016,united States
- in****@****mtx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- gothamtx.com
- HQ
- New York
Gotham Therapeutics Questions
Gotham Therapeutics's website is gothamtx.com
Gotham Therapeutics's LinkedIn profile is https://www.linkedin.com/company/gotham-therapeutics
Gotham Therapeutics's industry is
Biotechnology Research
Gotham Therapeutics's top competitors are
Petra Pharma,
Concarlo Therapeutics,
Lucerna, Inc.,
Prevail Therapeutics,
Bluerock Therapeutics,
Sarepta Therapeutics,
Meiragtx,
Anavo Therapeutics Bv,
Applied Therapeutics, Inc.,
Tessera Therapeutics.
Gotham Therapeutics's support email address is info@gothamtx.com
Gotham Therapeutics's categories are Biotechnology Research
Gotham Therapeutics's founding year is 2017
